News from northwest biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

26 Feb, 2019, 15:05 GMT NW Bio Hires David Innes As Vice President, Investor Relations

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


25 Jan, 2019, 14:17 GMT Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


14 Dec, 2018, 14:12 GMT NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


11 Dec, 2018, 14:00 GMT NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


31 May, 2018, 16:56 BST NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


29 May, 2018, 22:43 BST NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


08 Dec, 2015, 07:30 GMT NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations

Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...


08 Dec, 2015, 07:30 GMT NW Bio Statement Regarding Appointments

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...


17 Sep, 2013, 13:15 BST German Regulator Authorizes NW Bio's Phase III GBM Trial To Open

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor...


09 Jun, 2011, 01:32 BST Northwest Biotherapeutics Announces Change and Expansion of Management Team

- New CEO, COO, CSO and Senior VP Business Development Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has made changes and...


26 May, 2011, 01:21 BST Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

- Addition of Clinical Sites Ahead of Projections Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has accelerated the addition of...


18 May, 2011, 12:00 BST Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe

Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that it is partnering with Fraunhofer for production of DCVax(R)-L for brain...